Company / SG&A Expense
Astria Therapeutics, Inc. SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$34.5M
FY2024
5-year range
$11.8M / $34.5M
FY2020-FY2024
Trend
+34.0%
vs FY2023
Sector context
#177 of 213
Health Care
What the data says
Astria Therapeutics, Inc.'s sg&a expense of $34M is lower than 83% of companies in the Health Care sector (FY2024). SG&A Expense has increased for 5 consecutive years, from $9M in FY2019 to $34M in FY2024.
Based on SEC 10-K filings.
$34M in FY2024 with a 5-year CAGR of +31.5%.
Increased from $19M to $34M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +32.5%
- 5-Year CAGR
- +31.5%
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 213This company $34.5M Sector average $722.3M
▼
-95.2% below sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +31.5%, indicating consistent growth.
- In FY2024, sg&a expense increased 34.0% year-over-year.
- Ranks #177 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $34.5M | +34.0% |
| FY2023 | $25.7M | +33.6% |
| FY2022 | $19.2M | +29.9% |
| FY2021 | $14.8M | +25.0% |
| FY2020 | $11.8M | +35.0% |
| FY2019 | $8.8M | -6.0% |
| FY2018 | $9.3M | +4.7% |
| FY2017 | $8.9M | -11.8% |
| FY2016 | $10.1M | +17.1% |
| FY2015 | $8.6M | +43.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026